A Phase 1 interventional study of blinatumomab in Non-Hodgkin's Lymphoma, sponsored by Amgen. Completed at 17 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-02.
Sponsored by Amgen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Lymphoma, Non-Hodgkin by Amgen — none open to participants now, none under way, none of them phase 3. Lymphoma, Non-Hodgkin · Amgen.
Among the 20 studies in Lymphoma, Non-Hodgkin by Amgen, this one is the 9th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2017, is one of 7 in phase 1, and was the 19th registered.
2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →None of the 20 studies in Lymphoma, Non-Hodgkin by Amgen is open now. The open studies under Lymphoma, Non-Hodgkin, anywhere →
Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 10 · Phase 3 1 · Phase 4 1
First in 1999; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 39 across the 15 interventional studies, 1,837 across the 1 observational. Of the 19 that completed or were terminated, 8 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Lymphoma, Non-Hodgkin by Amgen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
Secondary Objectives:
Exploratory Objective:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In addition, they must have disease that is primary after initial therapy or have relapsed disease.
Small lymphocytic lymphoma
Responded to initial therapy for ≥ 1 year and relapsed after 2 or more lines of therapy, including an anti-CD20 monoclonal antibody
Exclusion Criteria:
History of other than their lymphoma with the exception of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: blinatumomab
Blinatumomab used as both continuous IV infusion and subcutaneous injection
Number of Participants With Dose Limiting-Toxicities (DLTs) After SC Administration
The occurrence of any of the following toxicities during the DLT evaluation period was considered a DLT, if judged by the investigator to be related to the administration of blinatumomab: * Death * Any toxicity, regardless of grade, that lead to a participant's removal from the study by the investigator and/or sponsor * Persistent Common Terminology Criteria for Adverse Events (CTCAE) grade \>/= 2 non-hematologic adverse events (AEs) that were deemed intolerable by the participant or the treating physician and that did not respond to appropriate medical management within 5 days and lead to treatment discontinuation * Recurrent grade 2 seizures * All grade 3 and 4 AEs and laboratory abnormalities, which occurred during the SC administration portion of the treatment period with exceptions noted in protocol section 6.2.1.2.3.
Time frame: Day 1 to Day 7 of Week 4
Number of Participants With DLTs CTCAE Grade ≥ 3 After SC Administration
All toxicities were graded using the CTCAE version 4.0: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = fatal.
Time frame: Day 1 to Day 7 of Week 4
Number of Participants With Treatment-emergent Adverse Events (TEAEs) After SC Administration
An AE was defined as any untoward medical occurrence in a clinical study participant. The AE did not necessarily have a causal relationship with study treatment. The definition of AEs included worsening of a pre-existing medical condition. TEAEs included AEs starting on or after first dose of investigational product and up to the end of study date. All AEs were graded using the CTCAE version 4.0: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = fatal.
Time frame: Day 1 to end of study (approximately 17 weeks)
Steady State Serum Concentration (Css) of Blinatumomab After cIV Administration
Summarized as the observed concentrations collected after 5 half-lives after the start of the IV infusion of each dose (i.e., 9, 28 and 112 μg/day).
Time frame: Once at any timepoint during Day 2 of Weeks 1, 2, 3, 5 and 6
Systemic Clearance (CL) of Blinatumomab After cIV Administration
Calculated as CL=R0/Css; where R0 is the infusion rate (μg/hr) and Css is the average Css. Both R0 and Css were dose-normalized to 112 μg/day for this calculation.
Time frame: Once at any timepoint during Day 2 of Weeks 1, 2, 3, 5 and 6
Maximum Observed Concentration (Cmax) of Blinatumomab After SC Administration
Time frame: Week 4 Day 1 (pre-dose and 1, 2, 4, 6, 8 and 12 hours post-dose) and Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)
Time at Which Cmax (Tmax) Occurred of Blinatumomab After SC Administration
Time frame: Week 4 Day 1 (pre-dose and 1, 2, 4, 6, 8 and 12 hours post-dose) and Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)
Area Under the Concentration-time Curve (AUC) of Blinatumomab After SC Administration for a Dosing Interval t (AUCt)
Estimated using the linear trapezoidal method; where t is a dosing interval. AUC over the dosing interval, t where t is 12 hours for Cohorts 1 and 2, 24 hours for Cohorts 3 and 4, and 48 hours for Cohort 5.
Time frame: Week 4 Day 1 (pre-dose and 1, 2, 4, 6, 8 and 12 hours post-dose) and Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)
Minimum Observed Concentration (Cmin) of Blinatumomab After SC Administration
Time frame: Week 4 Day 1 (pre-dose and 1, 2, 4, 6, 8 and 12 hours post-dose) and Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)
Apparent Clearance (CL/F) of Blinatumomab After SC Administration
Calculated as CL/F = Dose sc / AUCt-ss (at steady state).
Time frame: Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)
Volume of Distribution Based on Terminal Phase (Vz/F) of Blinatumomab After SC Administration
Calculated as Vz/F=CL/F / λz, where λz was the first-order rate constant estimated via linear regression of the terminal log-linear decay phase as determined from the noncompartmental analysis.
Time frame: Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)
Terminal Half-life (t1/2,z) of Blinatumomab After SC Administration
Calculated as t1/2,z = ln(2) / λz.
Time frame: Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)
Accumulation Ratio of Blinatumomab After SC Administration
Calculated as the ratio of AUCt (last SC dose; Week 4 Day 5) / AUC (first SC dose; Week 4 Day 1).
Time frame: Week 4 Day 1 (pre-dose and 1, 2, 4, 6, 8 and 12 hours post-dose) and Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)
Bioavailability (F) of SC Blinatumomab
Calculated as F = (CL \* AUCt-ss) / Dose sc.
Time frame: Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)
Maximum Tolerated Dose (MTD) of SC Blinatumomab
The MTD was defined as the highest dose level at which \</= 1 of 6 participants experienced a DLT.
Time frame: Day 1 to Day 7 of Week 4
Number of Participants With Anti-blinatumomab Antibody Formation After SC Administration
Time frame: Predose at the re-start of cIV infusion (Week 5 Day 1)
Overall Response Rate (ORR) After SC Administration
Percentage of participants achieving ORR (complete response \[CR\] + partial response \[PR\]) was determined by best overall response using Cheson criteria: * CR: disappearance of all evidence of disease. * PR: regression of measurable disease and no new sites. The 95% confidence interval (CI) was calculated using Clopper-Pearson exact CI. Participants were considered as non-responders if there was no response assessment available.
Time frame: Day 1 to end of study (approximately 17 weeks)
Of the 39 participants screened, 35 participants were enrolled at 10 centers in the United States, Europe and Australia between 18 September 2017 and 02 September 2021.
| Milestone | Blinatumomab Cohort 1 | Blinatumomab Cohort 2 | Blinatumomab Cohort 3 | Blinatumomab Cohort 4 | Blinatumomab Cohort 5 |
|---|---|---|---|---|---|
| Started | 7 | 8 | 8 | 6 | 6 |
| Started week 4 sc dosing | 6 | 7 | 7 | 6 | 5 |
| Started week 5-6 civ dosing | 6 | 5 | 6 | 6 | 5 |
| Completed | 5 | 4 | 5 | 6 | 5 |
| Not completed | 2 | 4 | 3 | 0 | 1 |
| Withdrew: Adverse event | 1 | 2 | 2 | 0 | 1 |
| Withdrew: Participant request | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Disease progression | 1 | 0 | 1 | 0 | 0 |
The occurrence of any of the following toxicities during the DLT evaluation period was considered a DLT, if judged by the investigator to be related to the administration of blinatumomab: * Death * Any toxicity, regardless of grade, that lead to a participant's removal from the study by the investigator and/or sponsor * Persistent Common Terminology Criteria for Adverse Events (CTCAE) grade \>/= 2 non-hematologic adverse events (AEs) that were deemed intolerable by the participant or the treating physician and that did not respond to appropriate medical management within 5 days and lead to treatment discontinuation * Recurrent grade 2 seizures * All grade 3 and 4 AEs and laboratory abnormalities, which occurred during the SC administration portion of the treatment period with exceptions noted in protocol section 6.2.1.2.3.
| Participants | Blinatumomab SC Cohort 1 | Blinatumomab SC Cohort 2 | Blinatumomab SC Cohort 3 | Blinatumomab SC Cohort 4 | Blinatumomab SC Cohort 5 |
|---|---|---|---|---|---|
| Number of Participants With Dose Limiting-Toxicities (DLTs) After SC Administration | 0 | 1 | 1 | 0 | 0 |
All toxicities were graded using the CTCAE version 4.0: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = fatal.
| Participants | Blinatumomab SC Cohort 1 | Blinatumomab SC Cohort 2 | Blinatumomab SC Cohort 3 | Blinatumomab SC Cohort 4 | Blinatumomab SC Cohort 5 |
|---|---|---|---|---|---|
| Number of Participants With DLTs CTCAE Grade ≥ 3 After SC Administration | 0 | 1 | 1 | 0 | 0 |
An AE was defined as any untoward medical occurrence in a clinical study participant. The AE did not necessarily have a causal relationship with study treatment. The definition of AEs included worsening of a pre-existing medical condition. TEAEs included AEs starting on or after first dose of investigational product and up to the end of study date. All AEs were graded using the CTCAE version 4.0: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = fatal.
| Participants | Blinatumomab SC Cohort 1 | Blinatumomab SC Cohort 2 | Blinatumomab SC Cohort 3 | Blinatumomab SC Cohort 4 | Blinatumomab SC Cohort 5 |
|---|---|---|---|---|---|
| Any TEAEs | 2 | 6 | 6 | 6 | 4 |
| Any TEAEs CTCAE Grade ≥ 3 | 1 | 1 | 2 | 1 | 0 |
Summarized as the observed concentrations collected after 5 half-lives after the start of the IV infusion of each dose (i.e., 9, 28 and 112 μg/day).
| pg/mL | Blinatumomab cIV Before SC Week 1 | Blinatumomab cIV Before SC Week 2 | Blinatumomab cIV Before SC Week 3 | Blinatumomab cIV After SC |
|---|---|---|---|---|
| Steady State Serum Concentration (Css) of Blinatumomab After cIV Administration | 238 ± 137 | 672 ± 94 | 2780 ± 87 | 2700 ± 85 |
Calculated as CL=R0/Css; where R0 is the infusion rate (μg/hr) and Css is the average Css. Both R0 and Css were dose-normalized to 112 μg/day for this calculation.
| L/hr | Blinatumomab cIV Before SC | Blinatumomab cIV After SC |
|---|---|---|
| Systemic Clearance (CL) of Blinatumomab After cIV Administration | 1.67 ± 111 | 1.73 ± 85 |
| pg/mL | Blinatumomab SC Cohort 1 | Blinatumomab SC Cohort 2 | Blinatumomab SC Cohort 3 | Blinatumomab SC Cohorts 4 and 5 | Blinatumomab SC Cohort 4 | Blinatumomab SC Cohort 5 |
|---|---|---|---|---|---|---|
| Week 4 Day 1 | 877 ± 88 | 1810 ± 93 | 2650 ± 98 | 4260 ± 103 | — | — |
| Week 4 Day 5 | 2070 ± 15 | 4340 ± 36 | 4290 ± 98 | — | 5690 ± 71 | 4340 ± 304 |
| hours | Blinatumomab SC Cohort 1 | Blinatumomab SC Cohort 2 | Blinatumomab SC Cohort 3 | Blinatumomab SC Cohorts 4 and 5 | Blinatumomab SC Cohort 4 | Blinatumomab SC Cohort 5 |
|---|---|---|---|---|---|---|
| Week 4 Day 1 | 5.0 (0.0 to 8.1) | 7.9 (1.0 to 8.1) | 12 (7.2 to 12) | 12 (1.9 to 12) | — | — |
| Week 4 Day 5 | 2.8 (0.0 to 8.0) | 4.0 (0.0 to 6.1) | 7.6 (6.0 to 12) | — | 8.0 (4.0 to 12) | 9.5 (2.2 to 12) |
Estimated using the linear trapezoidal method; where t is a dosing interval. AUC over the dosing interval, t where t is 12 hours for Cohorts 1 and 2, 24 hours for Cohorts 3 and 4, and 48 hours for Cohort 5.
| hr•pg/mL | Blinatumomab SC Cohort 1 | Blinatumomab SC Cohort 2 | Blinatumomab SC Cohort 3 | Blinatumomab SC Cohort 4 | Blinatumomab SC Cohort 5 |
|---|---|---|---|---|---|
| Week 4 Day 1 | 6080 ± 80 | 9430 ± 40 | — | — | — |
| Week 4 Day 5 | 19100 ± 21 | 40500 ± 41 | 72000 ± 92 | 90900 ± 77 | 90800 ± 236 |
| pg/mL | Blinatumomab SC Cohort 1 | Blinatumomab SC Cohort 2 | Blinatumomab SC Cohort 3 | Blinatumomab SC Cohort 4 | Blinatumomab SC Cohort 5 |
|---|---|---|---|---|---|
| Week 4 Day 1 | 651 ± 93 | 1470 ± 101 | — | — | — |
| Week 4 Day 5 | 1290 ± 30 | 2550 ± 41 | 1950 ± 94 | 2130 ± 104 | 147 ± 66 |
Calculated as CL/F = Dose sc / AUCt-ss (at steady state).
| L/hr | Blinatumomab SC Cohort 1 | Blinatumomab SC Cohort 2 | Blinatumomab SC Cohort 3 | Blinatumomab SC Cohort 4 | Blinatumomab SC Cohort 5 |
|---|---|---|---|---|---|
| Apparent Clearance (CL/F) of Blinatumomab After SC Administration | 5.85 ± 21 | 5.55 ± 41 | 6.25 ± 92 | 7.43 ± 77 | 7.43 ± 236 |
Calculated as Vz/F=CL/F / λz, where λz was the first-order rate constant estimated via linear regression of the terminal log-linear decay phase as determined from the noncompartmental analysis.
| liters | Blinatumomab SC Cohort 1 | Blinatumomab SC Cohort 2 | Blinatumomab SC Cohort 3 | Blinatumomab SC Cohort 4 | Blinatumomab SC Cohort 5 |
|---|---|---|---|---|---|
| Volume of Distribution Based on Terminal Phase (Vz/F) of Blinatumomab After SC Administration | 83.4 ± 19 | 100 ± 93 | 58.6 ± 115 | 120 ± 97 | 133 ± 9623 |
Calculated as t1/2,z = ln(2) / λz.
| hours | Blinatumomab SC Cohort 1 | Blinatumomab SC Cohort 2 | Blinatumomab SC Cohort 3 | Blinatumomab SC Cohort 4 | Blinatumomab SC Cohort 5 |
|---|---|---|---|---|---|
| Terminal Half-life (t1/2,z) of Blinatumomab After SC Administration | 9.87 ± 12 | 10.7 ± 22 | 7.30 ± 21 | 11.7 ± 30 | 9.20 ± 83 |
Calculated as the ratio of AUCt (last SC dose; Week 4 Day 5) / AUC (first SC dose; Week 4 Day 1).
| ratio | Blinatumomab SC Cohort 1 | Blinatumomab SC Cohort 2 | Blinatumomab SC Cohort 3 | Blinatumomab SC Cohort 4 | Blinatumomab SC Cohort 5 |
|---|---|---|---|---|---|
| Accumulation Ratio of Blinatumomab After SC Administration | 3.25 ± 61 | 4.14 ± 35 | 2.31 ± 63 | 1.71 ± 109 | 1.01 ± 107 |
Calculated as F = (CL \* AUCt-ss) / Dose sc.
| percent bioavailability | Blinatumomab SC Cohort 1 | Blinatumomab SC Cohort 2 | Blinatumomab SC Cohort 3 | Blinatumomab SC Cohort 4 | Blinatumomab SC Cohort 5 |
|---|---|---|---|---|---|
| Bioavailability (F) of SC Blinatumomab | 32.1 ± 38 | 22.5 ± 54 | 33.8 ± 215 | 24.6 ± 53 | 30.2 ± 180 |
The MTD was defined as the highest dose level at which \</= 1 of 6 participants experienced a DLT.
| μq | Blinatumomab SC Total |
|---|---|
| Maximum Tolerated Dose (MTD) of SC Blinatumomab | NA |
| Participants | Blinatumomab SC Cohort 1 | Blinatumomab SC Cohort 2 | Blinatumomab SC Cohort 3 | Blinatumomab SC Cohort 4 | Blinatumomab SC Cohort 5 |
|---|---|---|---|---|---|
| Number of Participants With Anti-blinatumomab Antibody Formation After SC Administration | 0 | 0 | 0 | 0 | 0 |
Percentage of participants achieving ORR (complete response \[CR\] + partial response \[PR\]) was determined by best overall response using Cheson criteria: * CR: disappearance of all evidence of disease. * PR: regression of measurable disease and no new sites. The 95% confidence interval (CI) was calculated using Clopper-Pearson exact CI. Participants were considered as non-responders if there was no response assessment available.
| percentage of participants | Blinatumomab SC Cohort 1 | Blinatumomab SC Cohort 2 | Blinatumomab SC Cohort 3 | Blinatumomab SC Cohort 4 | Blinatumomab SC Cohort 5 |
|---|---|---|---|---|---|
| Overall Response Rate (ORR) After SC Administration | 66.7 (22.3 to 95.7) | 71.4 (29.0 to 96.3) | 71.4 (29.0 to 96.3) | 83.3 (35.9 to 99.6) | 40.0 (5.3 to 85.3) |
Collected over Day 1 to end of study (approximately 17 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Blinatumomab cIV Before SC Week 1 | 1/35 (2.9%) | 5/35 (14.3%) | 23/35 (65.7%) |
| Blinatumomab cIV Before SC Week 2 | 0/34 (0%) | 5/34 (14.7%) | 22/34 (64.7%) |
| Blinatumomab cIV Before SC Week 3 | 0/33 (0%) | 8/33 (24.2%) | 23/33 (69.7%) |
| Blinatumomab SC Cohort 1 | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Blinatumomab SC Cohort 2 | 0/7 (0%) | 1/7 (14.3%) | 6/7 (85.7%) |
| Blinatumomab SC Cohort 3 | 0/7 (0%) | 1/7 (14.3%) | 6/7 (85.7%) |
| Blinatumomab SC Cohort 4 | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Blinatumomab SC Cohort 5 | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| Blinatumomab cIV After SC | 1/28 (3.6%) | 10/28 (35.7%) | 19/28 (67.9%) |
| Blinatumomab SC Total | 0/31 (0%) | 2/31 (6.5%) | 24/31 (77.4%) |
| Blinatumomab cIV Total | 2/35 (5.7%) | 18/35 (51.4%) | 34/35 (97.1%) |
| Blinatumomab SC + cIV Total | 2/35 (5.7%) | 19/35 (54.3%) | 35/35 (100%) |
| Event | Blinatumomab cIV Before SC Week 1 | Blinatumomab cIV Before SC Week 2 | Blinatumomab cIV Before SC Week 3 | Blinatumomab SC Cohort 1 | Blinatumomab SC Cohort 2 | Blinatumomab SC Cohort 3 | Blinatumomab SC Cohort 4 | Blinatumomab SC Cohort 5 | Blinatumomab cIV After SC | Blinatumomab SC Total | Blinatumomab cIV Total | Blinatumomab SC + cIV Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erosive oesophagitisGastrointestinal disorders | 0/35 | 0/34 | 0/33 | 0/6 | 1/7 | 0/7 | 0/6 | 0/5 | 0/28 | 1/31 | 0/35 | 1/35 |
| AphasiaNervous system disorders | 0/35 | 0/34 | 0/33 | 0/6 | 1/7 | 0/7 | 0/6 | 0/5 | 1/28 | 1/31 | 1/35 | 2/35 |
| SeizureNervous system disorders | 0/35 | 0/34 | 0/33 | 0/6 | 0/7 | 1/7 | 0/6 | 0/5 | 0/28 | 1/31 | 0/35 | 1/35 |
| HallucinationPsychiatric disorders | 0/35 | 0/34 | 0/33 | 0/6 | 0/7 | 1/7 | 0/6 | 0/5 | 0/28 | 1/31 | 0/35 | 1/35 |
| Nervous system disorderNervous system disorders | 0/35 | 1/34 | 2/33 | 0/6 | 0/7 | 0/7 | 0/6 | 0/5 | 1/28 | 0/31 | 4/35 | 4/35 |
| Cytokine release syndromeImmune system disorders | 0/35 | 0/34 | 2/33 | 0/6 | 0/7 | 0/7 | 0/6 | 0/5 | 2/28 | 0/31 | 2/35 | 2/35 |
| Cognitive disorderNervous system disorders | 0/35 | 0/34 | 0/33 | 0/6 | 0/7 | 0/7 | 0/6 | 0/5 | 2/28 | 0/31 | 2/35 | 2/35 |
| PyrexiaGeneral disorders | 0/35 | 1/34 | 0/33 | 0/6 | 0/7 | 0/7 | 0/6 | 0/5 | 1/28 | 0/31 | 2/35 | 2/35 |
| PneumoniaInfections and infestations | 1/35 | 1/34 | 0/33 | 0/6 | 0/7 | 0/7 | 0/6 | 0/5 | 0/28 | 0/31 | 2/35 | 2/35 |
| SepsisInfections and infestations | 0/35 | 0/34 | 1/33 | 0/6 | 0/7 | 0/7 | 0/6 | 0/5 | 1/28 | 0/31 | 2/35 | 2/35 |
| Event | Blinatumomab cIV Before SC Week 1 | Blinatumomab cIV Before SC Week 2 | Blinatumomab cIV Before SC Week 3 | Blinatumomab SC Cohort 1 | Blinatumomab SC Cohort 2 | Blinatumomab SC Cohort 3 | Blinatumomab SC Cohort 4 | Blinatumomab SC Cohort 5 | Blinatumomab cIV After SC | Blinatumomab SC Total | Blinatumomab cIV Total | Blinatumomab SC + cIV Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 7/35 | 3/34 | 11/33 | 1/6 | 0/7 | 1/7 | 0/6 | 0/5 | 4/28 | 2/31 | 17/35 | 18/35 |
| HeadacheNervous system disorders | 4/35 | 3/34 | 6/33 | 0/6 | 2/7 | 1/7 | 0/6 | 0/5 | 7/28 | 3/31 | 15/35 | 16/35 |
| ConstipationGastrointestinal disorders | 6/35 | 3/34 | 4/33 | 0/6 | 1/7 | 0/7 | 0/6 | 0/5 | 3/28 | 1/31 | 13/35 | 14/35 |
| Cytokine release syndromeImmune system disorders | 2/35 | 1/34 | 1/33 | 0/6 | 1/7 | 0/7 | 1/6 | 2/5 | 0/28 | 4/31 | 4/35 | 6/35 |
| TremorNervous system disorders | 4/35 | 1/34 | 9/33 | 0/6 | 0/7 | 0/7 | 2/6 | 0/5 | 4/28 | 2/31 | 12/35 | 12/35 |
| NeurotoxicityNervous system disorders | 3/35 | 1/34 | 3/33 | 1/6 | 1/7 | 0/7 | 2/6 | 0/5 | 2/28 | 4/31 | 5/35 | 7/35 |
| VertigoEar and labyrinth disorders | 1/35 | 0/34 | 2/33 | 0/6 | 2/7 | 0/7 | 0/6 | 0/5 | 1/28 | 2/31 | 3/35 | 3/35 |
| HypokalaemiaMetabolism and nutrition disorders | 0/35 | 1/34 | 0/33 | 0/6 | 2/7 | 0/7 | 0/6 | 0/5 | 0/28 | 2/31 | 1/35 | 3/35 |
| AphasiaNervous system disorders | 0/35 | 0/34 | 1/33 | 0/6 | 0/7 | 2/7 | 0/6 | 0/5 | 1/28 | 2/31 | 2/35 | 3/35 |
| InsomniaPsychiatric disorders | 3/35 | 2/34 | 0/33 | 0/6 | 1/7 | 1/7 | 1/6 | 0/5 | 2/28 | 3/31 | 7/35 | 9/35 |
All enrolled participants.
| Age, Customized(Participants) | Blinatumomab Cohort 1 | Blinatumomab Cohort 2 | Blinatumomab Cohort 3 | Blinatumomab Cohort 4 | Blinatumomab Cohort 5 | Total |
|---|---|---|---|---|---|---|
| 18 - 64 years | 5 | 5 | 3 | 3 | 5 | 21 |
| 65 - 74 years | 2 | 2 | 5 | 3 | 1 | 13 |
| 75 - 84 years | 0 | 1 | 0 | 0 | 0 | 1 |
| ≥ 85 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Blinatumomab Cohort 1 | Blinatumomab Cohort 2 | Blinatumomab Cohort 3 | Blinatumomab Cohort 4 | Blinatumomab Cohort 5 | Total |
|---|---|---|---|---|---|---|
| Female | 3 | 4 | 5 | 3 | 1 | 16 |
| Male | 4 | 4 | 3 | 3 | 5 | 19 |
| Ethnicity (NIH/OMB)(Participants) | Blinatumomab Cohort 1 | Blinatumomab Cohort 2 | Blinatumomab Cohort 3 | Blinatumomab Cohort 4 | Blinatumomab Cohort 5 | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 0 | 0 | 0 | 2 |
| Not Hispanic or Latino | 6 | 7 | 8 | 6 | 6 | 33 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Blinatumomab Cohort 1 | Blinatumomab Cohort 2 | Blinatumomab Cohort 3 | Blinatumomab Cohort 4 | Blinatumomab Cohort 5 | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 0 | 1 |
| Black (or African American) | 1 | 0 | 0 | 0 | 0 | 1 |
| Multiple | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 4 | 7 | 8 | 6 | 6 | 31 |
| Other | 2 | 0 | 0 | 0 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Data sharing details ↗ · www.amgen.com
Ran from Sep 2017 to primary completion in Sep 2021, 47 months.
Results were first posted in Feb 2024, 2 years 5 months after primary completion.
Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's 47 months is close to that.
Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Blinatumomab